Ardent Health (NYSE:ARDT) Releases FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: Ardent set EPS guidance of 0.900–1.270 (consensus 1.120) and revenue guidance of $6.4B–$6.7B (consensus $6.6B), signaling roughly in-line revenue outlook but a wide EPS range around estimates.
• Operational and market context: the company beat the last quarter's EPS forecast ($0.28 vs. $0.18), shares traded at $10.13 with a market cap of about $1.45B and a P/E of 10.6, while analysts’ consensus rating is Hold with an average price target of $14.25.

Ardent Health (NYSE:ARDT - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.900-1.270 for the period, compared to the consensus estimate of 1.120. The company issued revenue guidance of $6.4 billion-$6.7 billion, compared to the consensus revenue estimate of $6.6 billion.

Ardent Health Price Performance

NYSE ARDT traded up $0.15 on Tuesday, reaching $10.13. 492,301 shares of the stock traded hands, compared to its average volume of 393,411. The firm's fifty day simple moving average is $9.25 and its 200 day simple moving average is $9.85. The company has a quick ratio of 1.85, a current ratio of 1.97 and a debt-to-equity ratio of 0.64. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 10.55 and a beta of 0.93. Ardent Health has a 12 month low of $8.07 and a 12 month high of $15.48.

Ardent Health (NYSE:ARDT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.10. Ardent Health had a return on equity of 14.30% and a net margin of 2.15%.Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. As a group, research analysts predict that Ardent Health will post 1.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Zacks Research raised Ardent Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, March 25th. Leerink Partners reduced their price objective on Ardent Health from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Friday, March 6th. Royal Bank Of Canada reduced their price objective on Ardent Health from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Ardent Health from $12.00 to $11.00 and set a "neutral" rating for the company in a research note on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $14.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARDT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Ardent Health by 103.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company's stock valued at $194,000 after purchasing an additional 7,182 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Ardent Health by 1,684.9% during the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company's stock valued at $10,558,000 after purchasing an additional 724,841 shares during the last quarter. Jane Street Group LLC boosted its position in Ardent Health by 235.1% during the first quarter. Jane Street Group LLC now owns 57,468 shares of the company's stock valued at $790,000 after purchasing an additional 40,318 shares during the last quarter. Acadian Asset Management LLC boosted its position in Ardent Health by 574.9% during the first quarter. Acadian Asset Management LLC now owns 40,238 shares of the company's stock valued at $550,000 after purchasing an additional 34,276 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Ardent Health by 0.6% during the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company's stock valued at $3,918,000 after purchasing an additional 1,769 shares during the last quarter.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.